Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Additional patent protection for Ygalo® granted in Japan until October 2033

Thu, Mar 08, 2018 08:00 CET

Stockholm - March 8, 2018 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the Japanese Patent Office (JPO) recently issued a notice that they will grant an additional Japanese patent to Oncoeptides AB.The patent (application JP 2015-539556) covers inter alia the lyophilized formulation of Ygalo that is intended to be launched. The patent will expire in October 2033 "We are pleased to have received this patent notice which was in line with our expectations and it represents an important milestone for Ygalo’s future potential commercial value in this key territory. Last

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Additional patent protection for Ygalo® granted in Japan until October 2033

Subscribe

Media